Citius Pharmaceuticals Inc (CTXR)
0.5219
0.00 (0.00%)
USD |
NASDAQ |
Sep 27, 16:00
0.5218
0.00 (0.00%)
After-Hours: 20:00
Citius Pharmaceuticals Research and Development Expense (Annual): 14.82M for Sept. 30, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| September 30, 2023 | 14.82M |
| September 30, 2022 | 17.66M |
| September 30, 2021 | 12.24M |
| September 30, 2020 | 8.813M |
| September 30, 2019 | 8.597M |
| Date | Value |
|---|---|
| September 30, 2018 | 6.563M |
| September 30, 2017 | 2.936M |
| September 30, 2016 | 2.933M |
| September 30, 2015 | 1.797M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
8.597M
Minimum
2019
17.66M
Maximum
2022
12.43M
Average
12.24M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Agilent Technologies Inc | 481.00M |
| Seelos Therapeutics Inc | 30.12M |
| Cara Therapeutics Inc | 108.51M |
| Moleculin Biotech Inc | 19.49M |
| Citius Oncology Inc | -- |